GenSight Biologics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from GenSight Biologics SA
Access all reports
GenSight Biologics SA is a French biotechnology company focused on developing gene therapies for neurodegenerative diseases affecting vision. The company's primary area of research involves treatments for inherited retinal diseases, including Leber Hereditary Optic Neuropathy (LHON), a condition that leads to sudden vision loss. GenSight Biologics uses proprietary gene therapy platforms to target and potentially restore function in damaged retinal cells. Its therapies are designed to offer long-lasting effects with a single administration. The company is headquartered in Paris, France, and its shares are listed on Euronext Paris.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
SIGHT
Country
🇫🇷 France